Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials*

SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).

(2017) K. N. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

(2013) Ian F Tannock et al.   LANCET ONCOLOGY

The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer

(2012) Jatinder Goyal et al.   BJU INTERNATIONAL

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs

(2012) Saroj Niraula et al.   JOURNAL OF CLINICAL ONCOLOGY

From Efficacy to Effectiveness in the Face of Uncertainty

(2011) Benjamin Djulbegovic et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

(2010) Srikala S. Sridhar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer

(2010) Kim N. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials

(2010) Bostjan Seruga et al.   JOURNAL OF CLINICAL ONCOLOGY

What Constitutes Reasonable Evidence of Efficacy and Effectiveness to Guide Oncology Treatment Decisions?

(2010) D. Sargent   ONCOLOGIST

Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

(2008) D. R. Berthold et al.   CLINICAL CANCER RESEARCH

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy vs. effectiveness — docetaxel and prednisone in hormone refractory prostate cancer

(2008) Diana N Howard et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE